Search

651 Result(s)
Sort by

Interview with Michael Schmelmer

Interview with Michael Schmelmer

"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
Respiratory Diseases

Respiratory Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
emperor-preserved-heart-failure-full-data

emperor-preserved-heart-failure-full-data

Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
Interdisciplinary approach to CKM care

Interdisciplinary approach to CKM care

Explore the global impact of Cardiovascular- Kidney- Metabolic (CKM) syndrome, and the need for an integrated approach to manage these interconnected conditions. Insights from experts at Boehringer Ingelheim and George Washington University.
commitments to sustainable development

commitments to sustainable development

On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
George Okafo

George Okafo

My career challenge at Boehringer Ingelheim by George Okafo. Read it now!
Strategic-collaboration-with-EnaraBio

Strategic-collaboration-with-EnaraBio

Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
emperor-preserved-kidney-subanalysis

emperor-preserved-kidney-subanalysis

New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
biopharmaceuticals-in-china

biopharmaceuticals-in-china

Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
empulse-trial-benefit-acute-heart-failure

empulse-trial-benefit-acute-heart-failure

Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
DCRI-collaboration-empact-mi

DCRI-collaboration-empact-mi

Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
CARMELINA-elderly-analysis

CARMELINA-elderly-analysis

CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes